Background: The current pandemic of coronavirus disease 2019 has necessitated trial of several drugs searching for a potential cure. We have published an article to justify adoption of nitazoxanide/azithromycin for early cases of COVID-19 followed by two other articles providing the theoretical basis to add non-steroidal anti-inflammatory drugs to the protocol which is described in this manuscript.

Patients and methods: Twenty-two consented confirmed and highly suspected COVID-19 Egyptian patients including 11 adult males, 6 adult females, 2 pregnant patients as well as 3 children. All patients have received a 5-day-regimen of NSAIDs (diclofenac potassium, ibuprofen or ketoprofen)/nitazoxanide/azithromycin either in full or in part as illustrated in the manuscript. The primary endpoint of this protocol was full relief of all significant/hazardous COVID-19 symptoms and signs like fever, progressive cough, moderate/severe dyspnea or disturbed level of consciousness.

Results: The primary endpoint of this protocol was fully achieved in all patients within two weeks. Most of the patients treated early with the protocol have recovered during the five days; the lymphocytic count was significantly improved for those with prior lymphopenia. No significant adverse effects were reported.

Conclusion: A novel short course COVID-19 protocol using inexpensive FDA approved drugs is illustrated.